Safety issues and adverse reactions with osteoporosis management

References

• Rossini M, Di Munno O, Gatti D, et al. Optimising bisphosphonate treatment outcomes in postmenopausal osteoporosis: review and Italian experience. Clin Exp Rheumatol. 2011;29:728–735.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23–57.
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–1541.
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344–1352.
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–1249.
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, et al.. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927–2938.
   PubMed Web of Science ®Google Scholar
• Modi A, Siris ES, Steve Fan C-P, et al. Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis. Clin Ther. 2015;37:1228–1234.
   PubMed Web of Science ®Google Scholar
• Cadarette SM, Katz JN, Brookhart MA, et al. Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int. 2009;20:1735–1747.
   PubMed Web of Science ®Google Scholar
• Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf. 1996;14:158–170.
   PubMed Web of Science ®Google Scholar
• Wysowski DK. Oral bisphosphonates and oesophageal cancer. BMJ. 2010;341:4506.
   Web of Science ®Google Scholar
• Vestergaard P, Schwartz K, Rejnmark L, et al. Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study. J Oral Maxil Surg. 2012;70:821–829.
   PubMed Web of Science ®Google Scholar
• Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int. 1987;41:326–331.
   PubMed Web of Science ®Google Scholar
• Bertoldo F, Pancheri S, Zenari S, et al. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J Bone Miner Res. 2010;25:447–454.
   PubMed Web of Science ®Google Scholar
• Reid IR, Gamble GD, Mesenbrink P, et al. Characterization of and risk factors for the acute-phase response after Zoledronic acid. J Clin Endocrinol Metab. 2010;95:4380–4387.
   PubMed Web of Science ®Google Scholar
• Thiébaud D, Sauty A, Burckhardt P, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int. 1997;61:386–392.
   PubMed Web of Science ®Google Scholar
• Rossini M, Adami S, Viapiana O, et al. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration. J Bone Miner Res. 2012;27:227–230.
   PubMed Web of Science ®Google Scholar
• Bounameaux HM, Schifferli J, Montani JP, et al. Renal failure associated with intravenous diphosphonates. Lancet. 1983;1:471.
   PubMed Web of Science ®Google Scholar
• Kotteas E, Alamara C, Kiagia M, et al. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience. Anticancer Res. 2008;28:529–533.
   PubMed Web of Science ®Google Scholar
• Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22:503–508.
   PubMed Web of Science ®Google Scholar
• Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol. 2011;8:90–96.
   PubMed Web of Science ®Google Scholar
• Khan AA, Sandor GKB, Dore E, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2009;36:478–490.
   PubMed Web of Science ®Google Scholar
• Hoff AO, Toth B, Hu M, et al. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann New York Acad Sciences. 2011;1218:47–54.
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2007;22:1479–1491.
   PubMed Web of Science ®Google Scholar
• Edwards BJ, Hellstein JW, Jacobsen PL, et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2008;139:1674–1677.
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1–23.
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Åkesson K, Bouxsein M, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int. 2010;22:373–390.
   PubMed Web of Science ®Google Scholar
• Schilcher J, Koeppen V, Aspenberg P, et al. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86:100–107.
   PubMed Web of Science ®Google Scholar
• Meier RPH, Perneger TV, Stern R, et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012;172:930–936.
   PubMed Web of Science ®Google Scholar
• Gatti D, Adami S, Viapiana O, et al. The use of bisphosphonates in women: when to use and when to stop. Expert Opin Pharmacother. 2015;11:1–13.
   Google Scholar
• Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243–254.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Swern A, Hustad C, et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int. 2011;23:233–245.
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Cooper C, Thompson E, et al. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Practice. 2010;64:821–826.
   PubMed Web of Science ®Google Scholar
• Sharma A, Chatterjee S, Arbab-Zadeh A, et al. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis. Chest. 2013;144:1311–1322.
   PubMed Web of Science ®Google Scholar
• Kim DH, Rogers JR, Fulchino LA, et al. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One. 2015;10(4):e0122646. doi: 10.1371/journal.pone.0122646. eCollection.
   PubMed Web of Science ®Google Scholar
• Research C for DE and. Postmarket Drug Safety Information for Patients and Providers - Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa). 2015. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124165.htm.
   Google Scholar
• Caplan L, Pittman CB, Zeringue AL, et al. An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy. Mayo Clin Proc. 2010;85:341–348.
   PubMed Web of Science ®Google Scholar
• McKague M, Jorgenson D, Buxton KA. Ocular side effects of bisphosphonates. Can Fam Physician. 2010;56:1015–1017.
   PubMed Web of Science ®Google Scholar
• Brinkmeier T, Kügler K, Lepoittevin J-P, et al. Adverse cutaneous drug reaction to alendronate. Contact Derm. 2007;57:123–125.
   PubMed Web of Science ®Google Scholar
• Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int. 2009;20:239–244.
   PubMed Web of Science ®Google Scholar
• Adami S, Bertoldo F, Braga V, et al. 25-hydroxy vitamin D levels in healthy premenopausal women: association with bone turnover markers and bone mineral density. Bone. 2009;45:423–426.
   PubMed Web of Science ®Google Scholar
• Weaver CM, Alexander DD, Boushey CJ, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int. 2015. PMID: 26510847. [Epub ahead of print]
   Web of Science ®Google Scholar
• Rossini M, Adami S, Viapiana O, et al. Dose-dependent short-term effects of single high doses of oral vitamin D(3) on bone turnover markers. Calcif Tissue Int. 2012;91:365–369.
   PubMed Web of Science ®Google Scholar
• Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69:842–856.
   PubMed Web of Science ®Google Scholar
• Lewis JR, Zhu K, Prince RL. Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation. J Bone Miner Res. 2012;27:719–722.
   PubMed Web of Science ®Google Scholar
• Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med. 1997;126:497–504.
   PubMed Web of Science ®Google Scholar
• Candelas G, Martinez-Lopez JA, Rosario MP, et al. Calcium supplementation and kidney stone risk in osteoporosis: a systematic literature review. Clin Exp Rheumatol. 2012;30:954–961.
   PubMed Web of Science ®Google Scholar
• Finkielstein VA, Goldfarb DS. Strategies for preventing calcium oxalate stones. Cmaj. 2006;174:1407–1409.
   PubMed Web of Science ®Google Scholar
• Bolland MJ, Grey A, Reid IR. Calcium supplements and cardiovascular risk: 5 years on. Ther Adv Drug Saf. 2013;4:199–210.
   PubMedGoogle Scholar
• Bolland MJ, Leung W, Tai V, et al. Calcium intake and risk of fracture: systematic review. BMJ. 2015;351:4580.
   PubMed Web of Science ®Google Scholar
• Grey A, Bolland M. Web of industry, advocacy, and academia in the management of osteoporosis. BMJ. 2015;351:3170.
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol. 2014;142:142–154.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone. 2010;47:729–735.
   PubMed Web of Science ®Google Scholar
• Palacios S, Silverman SL, de Villiers TJ, et al. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause. 2015;22:806–813.
   PubMed Web of Science ®Google Scholar
• Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost. 2008;99:338–342.
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–137.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381:1827–1834.
   PubMed Web of Science ®Google Scholar
• Vogel VG. Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene. Clin Interv Aging. 2008;3:601–609.
   PubMed Web of Science ®Google Scholar
• Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104:439–446.
   PubMed Web of Science ®Google Scholar
• Gatti D, Viapiana O, Idolazzi L, et al. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab. 2011;96:1555–1559.
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441.
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9–17.
   PubMed Web of Science ®Google Scholar
• Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028–2039.
   PubMed Web of Science ®Google Scholar
• Blick SKA, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. Drugs. 2008;68:2709–2737.
   PubMed Web of Science ®Google Scholar
• Hajime M, Okada Y, Mori H, et al. A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. J Bone Miner Metab. 2014;32:601–604.
   PubMed Web of Science ®Google Scholar
• Karatoprak C, Kayatas K, Kilicaslan H, et al. Severe hypercalcemia due to teriparatide. Indian J Pharmacol. 2012;44:270–271.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Tsujimoto M, Sowa H. Safety of daily teriparatide treatment: a post hoc analysis of a Phase III study to investigate the possible association of teriparatide treatment with calcium homeostasis in patients with serum procollagen type I N-terminal propeptide elevation. Clin Interv Aging. 2015;10:1101–1109.
   PubMed Web of Science ®Google Scholar
• Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30:312–321.
   PubMed Web of Science ®Google Scholar
• Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004;32:426–438.
   PubMed Web of Science ®Google Scholar
• Vahle JL, Zuehlke U, Schmidt A, et al. Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res. 2008;23:2033–2039.
   PubMed Web of Science ®Google Scholar
• Amugongo SK, Yao W, Jia J, et al. Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats. Bone. 2014;67:257–268.
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–765.
   PubMed Web of Science ®Google Scholar
• Dave V, Chiang CY, Booth J, et al. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5. Am J Nephrol. 2015;41:129–137.
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015. [ [Epub ahead of print]]. doi:10.1007/s00198-015-3234-7.
   Web of Science ®Google Scholar
• Qi W-X, Tang L-N, He A-N, et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014;19:403–410.
   PubMed Web of Science ®Google Scholar
• Aspenberg P. Denosumab and atypical femoral fractures. Acta Orthop. 2014;85:1–1.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Chen C, Zhang J, et al. Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. Int J Clin Exp Pathol. 2014;7:2113–2122.
   PubMed Web of Science ®Google Scholar
• EMA. Questions and answers on the review of calcitonin-containing medicines [Internet]. 2013 [cited 2016 Jan 6]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Calcitonin_31/WC500146171.pdf.
   Google Scholar
• EMA. Protelos/Osseor to remain available but with further restrictions [Internet]. 2014 [cited 2016 Jan 6]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Protelos_and_Osseor/European_Commission_final_decision/WC500173034.pdf.
   Google Scholar
• Glüer -C-C, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res. 2013;28:1355–1368.
   PubMed Web of Science ®Google Scholar
• Saag KG, Zanchetta JR, Devogelaer J-P, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60:3346–3355.
   PubMed Web of Science ®Google Scholar
• Adami S, Bertoldo F, Gatti D, et al. Treatment thresholds for osteoporosis and reimbursability criteria: perspectives associated with fracture risk-assessment tools. Calcif Tissue Int. 2013;93:195–200.
   PubMed Web of Science ®Google Scholar
• Cosman F, De Beur SJ, LeBoff MS, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014;25:2359–2381.
   PubMed Web of Science ®Google Scholar
• Adler RA, Fuleihan GE-H, Bauer DC, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2015; doi:10.1002/jbmr.2708. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Adami S, Idolazzi L, Fracassi E, et al. Osteoporosis treatment: when to discontinue and when to re-start. Bone Res. 2013;4:323–335.
   Web of Science ®Google Scholar
• Rossini M, Lello S, Sblendorio I, et al. Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture. Drug Des Devel Ther. 2013;7:601–610.
   PubMed Web of Science ®Google Scholar
• Rossini M, Viapiana O, Adami S, et al. Effects of denosumab on peripheral lymphocyte subpopulations. Endocrine. 2015. PMID: 26289128. [Epub ahead of print]
   Google Scholar